David Kerstein
Keine laufenden Positionen mehr
Profil
David P.
Kerstein worked as a Senior Medical Director-Clinical Research at ARIAD Pharmaceuticals, Inc. from 2014 to 2017.
He also worked as a Director-Regulatory Affairs & Clinical Development at Boston Biomedical, Inc. He then worked as a Senior Medical Director-Clinical Research at Takeda Pharmaceuticals International, Inc. from 2017 to 2018.
After that, he worked as the Chief Medical Officer & Senior Vice President at Anchiano Therapeutics Ltd.
Dr. Kerstein is currently working as the Chief Medical Officer at Theseus Pharmaceuticals, Inc. Dr. Kerstein holds a graduate degree from Tufts University and a doctorate degree from Tufts University School of Medicine.
Ehemalige bekannte Positionen von David Kerstein
| Unternehmen | Position | Ende |
|---|---|---|
| THESEUS PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 07.12.2023 |
Takeda Pharmaceuticals International, Inc.
 Takeda Pharmaceuticals International, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Takeda Pharmaceutical Co., Ltd., Takeda Pharmaceuticals International, Inc. provides management consulting for pharmaceutical businesses. The company is based in Deerfield, IL. | Corporate Officer/Principal | 01.11.2018 |
| ARIAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2017 |
Boston Biomedical, Inc.
 Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | General Counsel | - |
| ANCHIANO THERAPEUTICS LTD. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von David Kerstein
| Tufts University School of Medicine | Doctorate Degree |
| Tufts University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Anchiano Therapeutics Ltd.
 Anchiano Therapeutics Ltd. BiotechnologyHealth Technology Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company, which engages in tin the discovery, development and commercialization of drugs for cancer-related diseases. Its products include two drugs for cancer BC-819 and BC-821. The company was founded by Avraham Hochberg in 2004 and is headquartered in Jerusalem, Israel. | Health Technology |
Takeda Pharmaceuticals International, Inc.
Takeda Pharmaceuticals International, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Takeda Pharmaceutical Co., Ltd., Takeda Pharmaceuticals International, Inc. provides management consulting for pharmaceutical businesses. The company is based in Deerfield, IL. | Commercial Services |
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA. | Health Technology |
Boston Biomedical, Inc.
Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Commercial Services |
Theseus Pharmaceuticals, Inc.
 Theseus Pharmaceuticals, Inc. BiotechnologyHealth Technology Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA. | Health Technology |
